D. Boral Capital analyst Jason Kolbert raised the firm’s price target on CervoMed (CRVO) to $31 from $15 and keeps a Buy rating on the shares. The firm increased its probability of clinical success for neflamapimod in dementia with Lewy bodies to 30% from 15% based on recently presented data. The recent results “materially strengthen” the late-stage outlook for the program and address uncertainties, the analyst tells investors in a research note. D. Boral points out that the underdosed patients performed like placebo, while fully dosed patients drove the efficacy signal.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target
- CervoMed price target lowered to $16 from $20 at Roth Capital
- CervoMed Reports Promising Trial Results and Financial Update
- CervoMed reports Q2 EPS (70c), consensus (50c)
- CervoMed expects cash to fund operations into Q3 of 2026